48
Participants
Start Date
November 30, 2013
Primary Completion Date
March 31, 2015
Study Completion Date
December 31, 2015
TetraVax-DV-TV003
TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10\^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
rDEN2∆30-7169
The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
Placebo
The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health, Baltimore
University of Vermont Vaccine Testing Center, Burlington
National Institute of Allergy and Infectious Diseases (NIAID)
NIH